Dan Zhao

机构：Hebei Medical University, The University of Texas MD Anderson Cancer Center, Capital Medical University, Gene Therapy Laboratory, Second Hospital of Hebei Medical University, Huazhong University of Science and Technology · ORCID：0000-0001-7066-9058

发表论文 400 篇 · 总被引 7347 次 · h-index 46

代表论文

• Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial (2025 · The Lancet Oncology · 被引 24)
• Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial (2026 · Journal of Clinical Oncology · 被引 3)
• Stromal Laminin Subunit Alpha 3 is a Novel Prognostic Marker for Breast Cancer (2026 · Clinical Medicine Insights Oncology)
• Multi-Omic Analysis of Cerebrospinal Fluid Metabolites in Autism Spectrum Disorder: Biomarker Identification, Metabolic Genetics Insights, and Network Toxicology (2026 · Genes)
• Abstract A046: CLDN18.2 Expression in PDAC: KRAS Independence and Stage IV Prognostic Value (2026 · Clinical Cancer Research)
• Abstract B036: Allele Specific Characteristics of KRAS Q61 Mutated Gastrointestinal Malignancies and Clinical Outcomes and Transcriptomic Features (2026 · Clinical Cancer Research)